share_log

Is Now The Time To Put China Traditional Chinese Medicine Holdings (HKG:570) On Your Watchlist?

Is Now The Time To Put China Traditional Chinese Medicine Holdings (HKG:570) On Your Watchlist?

现在是时候将中国中医药控股公司(HKG:570)列入您的观察名单了吗?
Simply Wall St ·  2022/06/29 19:00

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.

对于初学者来说,收购一家向投资者讲述一个好故事的公司似乎是一个好主意(也是一个令人兴奋的前景),即使它目前没有收入和利润的记录。但现实是,当一家公司每年亏损时,在足够长的时间内,投资者通常会承担他们的损失份额。一家亏损的公司还没有用盈利来证明自己,最终外部资本的流入可能会枯竭。

If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in China Traditional Chinese Medicine Holdings (HKG:570). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.

如果这种公司不是你的风格,你喜欢能产生收入,甚至能赚钱的公司,那么你很可能会对中国中医药控股有限公司(HKG:570)。虽然利润不是投资时应该考虑的唯一指标,但值得表彰能够持续产生利润的企业。

Check out our latest analysis for China Traditional Chinese Medicine Holdings

查看我们对中国中医药控股有限公司的最新分析

How Quickly Is China Traditional Chinese Medicine Holdings Increasing Earnings Per Share?

中国中医药控股的每股收益增长速度有多快?

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Over the last three years, China Traditional Chinese Medicine Holdings has grown EPS by 8.7% per year. That's a pretty good rate, if the company can sustain it.

如果你相信市场是模糊有效的,那么从长期来看,你会认为一家公司的股价会跟随其每股收益(EPS)的结果。因此,有经验的投资者在进行投资研究时密切关注公司每股收益是合理的。在过去的三年里,中国中医药控股每年以8.7%的速度增长每股收益。这是一个相当不错的比率,如果公司能够维持下去的话。

It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. On the one hand, China Traditional Chinese Medicine Holdings' EBIT margins fell over the last year, but on the other hand, revenue grew. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead.

看一看息税前利润(EBIT)利润率和收入增长,对了解公司增长的质量通常是有帮助的。一方面,中国中医药控股去年息税前利润下降,但另一方面,收入增长。如果息税前利润能够保持平衡,收入增长继续下去,那么我们应该会看到未来更光明的日子。

You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.

你可以在下面的图表中看到该公司的收入和收益增长趋势。点击图表查看确切的数字。

SEHK:570 Earnings and Revenue History June 29th 2022
联交所:570盈利及收入历史2022年6月29日

In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of China Traditional Chinese Medicine Holdings' forecast profits?

在投资中,就像在生活中一样,未来比过去更重要。那么为什么不来看看这个免费中国中医药控股有限公司的互动可视化预测利润?

Are China Traditional Chinese Medicine Holdings Insiders Aligned With All Shareholders?

中国中医药控股的内部人士是否与所有股东一致?

It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. So it is good to see that China Traditional Chinese Medicine Holdings insiders have a significant amount of capital invested in the stock. Holding CN¥766m worth of stock in the company is no laughing matter and insiders will be committed in delivering the best outcomes for shareholders. This should keep them focused on creating long term value for shareholders.

公司领导人以股东的最佳利益行事是必要的,因此,内部投资总是对市场起到安抚作用。因此,看到中国中医药控股的内部人士有大量资金投资于该股是件好事。持有该公司价值7.66亿元的股票不是一件好笑的事情,内部人士将致力于为股东带来最好的结果。这应该会让他们专注于为股东创造长期价值。

Is China Traditional Chinese Medicine Holdings Worth Keeping An Eye On?

中国中医药控股值得关注吗?

One important encouraging feature of China Traditional Chinese Medicine Holdings is that it is growing profits. If that's not enough on its own, there is also the rather notable levels of insider ownership. These two factors are a huge highlight for the company which should be a strong contender your watchlists. You should always think about risks though. Case in point, we've spotted 1 warning sign for China Traditional Chinese Medicine Holdings you should be aware of.

中国中医药控股公司令人鼓舞的一个重要特征是,它的利润在不断增长。如果这本身还不够,还有相当显著的内部人持股水平。这两个因素对该公司来说是一个巨大的亮点,它应该是你观察名单上的一个强有力的竞争者。不过,你应该始终考虑风险。举个例子,我们发现中国中医药控股有限公司的1个警告标志你应该意识到。

The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.

投资的美妙之处在于,你几乎可以投资任何你想投资的公司。但如果你更愿意关注那些表现出内幕收购的股票,这里有一份过去三个月内有内幕收购的公司名单。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

请注意,本文中讨论的内幕交易指的是相关司法管辖区内的应报告交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发